(Q37448263)

20 August 2017

1 reference

title

Clinical consequences of polymorphic drug oxidation (English)

1 reference

20 August 2017

Alván G

1

1 reference

20 August 2017

1 January 1991

1 reference

Fundamental and Clinical Pharmacology

20 August 2017

1 reference

20 August 2017

5

1 reference

20 August 2017

209-228

1 reference

20 August 2017

3

1 reference

Importance of genetic factors in the regulation of diazepam metabolism: relationship to S-mephenytoin, but not debrisoquin, hydroxylation phenotype.

20 August 2017

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.1991.TB00713.X

The debrisoquine hydroxylation test predicts steady-state plasma levels of desipramine

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.1991.TB00713.X

Sparteine oxidation is practically abolished in quinidine-treated patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.1991.TB00713.X

The influence of enzyme induction on polymorphic sparteine oxidation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.1991.TB00713.X

Genetically-determined interaction between propafenone and low dose quinidine: role of active metabolites in modulating net drug effect

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.1991.TB00713.X

Poor hydroxylator phenotypes of debrisoquine and S-mephenytoin are not over-represented in a group of patients with Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.1991.TB00713.X

In vitro metabolism of the biguanide antimalarials in human liver microsomes: evidence for a role of the mephenytoin hydroxylase (P450 MP) enzyme

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.1991.TB00713.X

Lack of evidence for polymorphism in metoprolol metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.1991.TB00713.X

Polymorphic drug oxidation: pharmacokinetic basis and comparison of experimental indices

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.1991.TB00713.X

Defective metabolism of metoprolol in poor hydroxylators of debrisoquine

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.1991.TB00713.X

Differential stereoselective metabolism of metoprolol in extensive and poor debrisoquin metabolizers

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.1991.TB00713.X

Timolol and atenolol: relationships between oxidation phenotype, pharmacokinetics and pharmacodynamics

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.1991.TB00713.X

Interindividual variations in metoprolol metabolism--some clinical and other observations

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.1991.TB00713.X

Genetically determined oxidation capacity and the disposition of debrisoquine

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.1991.TB00713.X

Quinidine and the identification of drugs whose elimination is impaired in subjects classified as poor metabolizers of debrisoquine

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.1991.TB00713.X

Debrisoquine oxidation phenotype and susceptibility to lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.1991.TB00713.X

A family study of genetic and environmental factors determining polymorphic hydroxylation of debrisoquin

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.1991.TB00713.X

Polymorphic oxidation of sparteine and debrisoquine: Related pharmacogenetic entities

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.1991.TB00713.X

10.1111/J.1472-8206.1991.TB00713.X

21 January 2018

Identifiers

DOI

1 reference

20 August 2017

1 reference

PubMed ID

1937350